Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human prostate cancer cells treated with resveratrol

ABSTRACT: Arrays for Expression levels of androgen-responsive genes in LNCaP cells exposed to dihydrotestosterone, R1881. Gene-expression changes in LNCaP treated with 1 nmol/L R1881 at 7, 9, 18, 24, 50, and 72 hours; 10 nmol/L dihydrotestosterone at 18 and 50 hours; 100 nmol/L dihydrotestosterone and 1 5mol/L dihydrotestosterone at 24 hours; and androgen deprivation at 46 and 70 hours.

ORGANISM(S): Homo sapiens

SUBMITTER: Janos Demeter

PROVIDER: E-SMDB-3259 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Resveratrol-induced gene expression profiles in human prostate cancer cells.

Jones Sunita B SB DePrimo Samuel E SE Whitfield Michael L ML Brooks James D JD

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20050301 3

<h4>Objective</h4>The transhydroxystilbene resveratrol is found at high levels in red wine and grapes, and red wine consumption may be inversely associated with prostate cancer risk. To gain insights into the possible mechanisms of action of resveratrol in human prostate cancer, we did DNA microarray analysis of the temporal transcriptional program induced by treatment of the human prostate cancer cell line LNCaP with resveratrol.<h4>Methods</h4>Spotted DNA microarrays containing over 42,000 ele ...[more]

PMID: 15767336

Similar Datasets

Androgen arrays for Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer

Project description:Arrays for Expression levels of androgen-responsive genes in LNCaP cells exposed to dihydrotestosterone, R1881. Gene-expression changes in LNCaP treated with 1 nmol/L R1881 at 7, 9, 18, 24, 50, and 72 hours; 10 nmol/L dihydrotestosterone at 18 and 50 hours; 100 nmol/L dihydrotestosterone and 1 5mol/L dihydrotestosterone at 24 hours; and androgen deprivation at 46 and 70 hours. This set corresponds to Figure 2 of the publication. An all pairs experiment design type is where all labeled extracts are compared to every other labeled extract. Keywords: all_pairs

2006-02-25 | GSE4300 | GEO

Androgen arrays for Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer

2006-02-24 | E-GEOD-4300 | biostudies-arrayexpress

Androgen receptor-coregulators hormone responsiveness LNCaP / GSF

Project description:The text description is: LNCaP are androgen receptor expressing prostate carcinoma cells. Genital skin fibroblasts also express the androgen receptor. Cells were either proliferating or they were G0-arrested. Treatment of cells was performed with either the androgen DHT (dihydrotestosterone), the androgen analogue R1881 (methyltrienolone), or the solvent ethanol. Some hybridizations were performed in the type 1 design. In these cases, the hormone treated sample was hybridized against the ethanol treated sample on the same microarray. Hormone mediated induction or repression of gene transcription can directly be deduced from R/G normalized ratios on arrays. For other experiments, the ethanol treated control and the hormone treated experiment were hybridized on separate microarrays against a common reference of RNA. This reference was composed out of common reference batch CRG (50%) and a fibroblast RNA (50%). This reference was called mixed reference. For all experiments, the same batch of mixed reference was used. A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Compound Based Treatment: Ethanol, R1881 (methyltrienolone), or DHT (dihydrotestosterone) Cell Line: LNCaP (prostate cancer) or foreskin fibroblasts Culture Synchrony: proliferation / Go-arrest Keywords: compound_treatment_design

2006-10-12 | GSE4454 | GEO

Androgen receptor-coregulators hormone responsiveness LNCaP / GSF

2010-07-01 | E-GEOD-4454 | biostudies-arrayexpress

Transcription profiling of human androgen receptor expressing prostate carcinoma cell line LNCaP and normal human foreskin fibroblasts expressing the androgen receptor treated with dihydrotestosterone (DHT), ethanol, or untreated vs. a common reference, see E-SMDB-3636

Project description:The text description is: LNCaP are androgen receptor expressing prostate carcinoma cells. Genital skin fibroblasts also express the androgen receptor. Cells were either proliferating or they were G0-arrested. Treatment of cells was performed with either the androgen DHT (dihydrotestosterone), the androgen analogue R1881 (methyltrienolone), or the solvent ethanol. Hybridizations were performed in the type 1 design for arrays # 1-8. In these cases, the hormone treated sample was hybridized against the ethanol treated sample on the same microarray. Hormone mediated induction or repression of gene transcription can directly be deduced from R/G normalized ratios on arrays. For other experiments (#9-24), the ethanol treated control and the hormone treated experiment were hybridized on separate microarrays against a common reference of RNA. This reference was composed out of common reference batch CRG (50%) and a fibroblast RNA (50%). This reference was called mixed reference. For all experiments, the same batch of mixed reference was used.

2006-11-06 | E-SMDB-3637 | biostudies-arrayexpress

Gene expression of LNCaP cells grown in 2D cultures and polyethlene glycol-based hydrogels with the presence of synthetic androgen, R1881

Project description:Analysis of LNCaP cell molecular differences and their response to R1881 in 2D and 3D cultures. Androgen regulated genes were differentially expressed between 2D and 3D cultures. These results provide insights into factors that influence the expression of androgen regulated genes In this study, LNCaP cells cultured in tissue culture plastic (2D) and in the hydrogel (3D) were maintained up to 3 days and 24 days respectively in serum containing media before they were androgen-starved for 48 hours. Cells were either treated with 1nM R1881 or continued to be androgen-deprived (without R1881 with 0.008% ethanol) for another 48 hours prior to cell harvest for gene expression analysis. Biological triplicates were prepared for each condition.

2013-02-04 | E-GEOD-33610 | biostudies-arrayexpress

Gene expression of LNCaP cells grown in polyethlene glycol-based hydrogels alone (monocultures) and grown with human osteoblasts as tissue engineered bone (co-culture) with the presence of synthetic androgen, R1881

Project description:Analysis of LNCaP cell molecular differences in monocultures and in co-cultures in the presence of R1881. Human osteoblast molecular signatures were also identified from the tissue engineered bone monocultures. LNCaP cells molecular profile was altered by co-culturing with human osteoblasts compared to LNCaP monocultures with or without R1881 stimulations. These results provide insights into the behavioral change of LNCaP cells in a bone-like microenvironment. In this study, LNCaP cells cultured in the hydrogel were prepared and co-cultured with or without human osteoblasts (in the form oftissue engineered bone). Similarly, tissue engineered bone monocultures were also prepared 4-6 weeks earlier before co-culturing with the LNCaP cells. These cultures were maintained up to 24 days in RPMI growth media (+10% FBS) before they were androgen-starved for 48 hours. Cells were either treated with 1nM R1881 or continued to be androgen-deprived (without R1881 with 0.008% ethanol) for another 48 hours prior to cell harvest for gene expression analysis. Biological triplicates were prepared for each condition.

2014-05-13 | E-GEOD-44143 | biostudies-arrayexpress

Prostate cancer cell line LNCaP treated for 2, 4, 6, 8 h with the synthetic androgen R1881 (1nM)

Project description:Time series of the prostate cancer cell line LNCaP, treated for 2, 4, 6 and 8 hours with the synthetic androgen R1881. As control, the cells were cultured for 2, 4, 6 and 8 hours in the presence of the same concentration of solvent (ethanol). With this short treatment time, we aimed to identify mainly direct targets of the androgen receptor. LNCaP has a very low growth rate in steroid stripped medium and resumes growth on addition of androgens. Keywords: Time course

2006-04-01 | GSE4027 | GEO

Hormone-Independence of Prostate Cancer Cells is Supported by the Androgen Receptor without Binding to Classical Response Elements

Project description:Treatment of late passage (LP50) LNCaP cells with R1881 (androgen) and AR shRNA identified a gene program controlled by androgen receptor in the absence of androgen. Gene expression in late passage (LP50) LNCaP cells that had enhanced androgen-independent growth was determined in androgen-depleted medium in response to R1881 or AR knock down via AR shRNA

2011-01-28 | E-GEOD-22483 | biostudies-arrayexpress

Hormone-Independence of Prostate Cancer Cells is Supported by the Androgen Receptor without Binding to Classical Response Elements

Project description:Treatment of late passage (LP50) LNCaP cells with R1881 (androgen) and AR shRNA identified a gene program controlled by androgen receptor in the absence of androgen.

2011-01-28 | GSE22483 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data